Evidence map›Paper›PMID 37993474›Full record

ArticleScientific reports2023

Bioinformatics analysis and machine learning approach applied to the identification of novel key genes involved in non-alcoholic fatty liver disease.

Elham Nazari, Ghazaleh Khalili-Tanha, Alireza Asadnia, Ghazaleh Pourali, Mina Maftooh, Majid Khazaei, Mohammadreza Nasiri, Seyed Mahdi Hassanian, Majid Ghayour-Mobarhan, Gordon A Ferns and 2 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 4 countries.

Elham Nazari *Department of Health Information Technology and Management, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Ghazaleh Khalili-Tanha *Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Alireza AsadniaMedical Genetics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Ghazaleh PouraliMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mina MaftoohMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid KhazaeiMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Mohammadreza NasiriRecombinant Proteins Research Group, The Research Institute of Biotechnology, Ferdowsi University of Mashhad, Mashhad, Iran.
Seyed Mahdi HassanianMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Majid Ghayour-MobarhanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Gordon A FernsDivision of Medical Education, Brighton & Sussex Medical School, Falmer, Brighton, BN1 9PH, Sussex, UK.
Mohammad Ali KianiDepartment of Pediatrics, Ghaem Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.
Amir AvanMetabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. amir_avan@yahoo.com.
Mashhad University of Medical Sciences · IRBrighton and Sussex Medical School · GBFerdowsi University of Mashhad · IRShahid Beheshti University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Non-alcoholic fatty liver disease (NAFLD) comprises a range of chronic liver diseases that result from the accumulation of excess triglycerides in the liver, and which, in its early phases, is categorized NAFLD, or hepato-steatosis with pure fatty liver. The mortality rate of non-alcoholic steatohepatitis (NASH) is more than NAFLD; therefore, diagnosing the disease in its early stages may decrease liver damage and increase the survival rate. In the current study, we screened the gene expression data of NAFLD patients and control samples from the public dataset GEO to detect DEGs. Then, the correlation betweenbetween the top selected DEGs and clinical data was evaluated. In the present study, two GEO datasets (GSE48452, GSE126848) were downloaded. The dysregulated expressed genes (DEGs) were identified by machine learning methods (Penalize regression models). Then, the shared DEGs between the two training datasets were validated using validation datasets. ROC-curve analysis was used to identify diagnostic markers. R software analyzed the interactions between DEGs, clinical data, and fatty liver. Ten novel genes, including ABCF1, SART3, APC5, NONO, KAT7, ZPR1, RABGAP1, SLC7A8, SPAG9, and KAT6A were found to have a differential expression between NAFLD and healthy individuals. Based on validation results and ROC analysis, NR4A2 and IGFBP1b were identified as diagnostic markers. These key genes may be predictive markers for the development of fatty liver. It is recommended that these key genes are assessed further as possible predictive markers during the development of fatty liver.

Indexed as

Non-alcoholic Fatty Liver DiseaseAdaptor Proteins, Signal TransducingAntigens, NeoplasmATP-Binding Cassette TransportersComputational BiologyHistone AcetyltransferasesHumansLiver CirrhosisMachine LearningRNA-Binding ProteinsABCF1 protein, humanAdaptor Proteins, Signal TransducingAntigens, NeoplasmATP-Binding Cassette TransportersHistone AcetyltransferasesKAT6A protein, humanKAT7 protein, humanRNA-Binding ProteinsSART3 protein, humanSPAG9 protein, human

Identifiers

PMID37993474
PMCPMC10665370
OpenAlexW4388900094

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.